We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for Cell and Gene Therapy Production

A PCR Machine.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B),  announced the recent launch of the Vericheck ddPCR™ Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. The kits provide rapid, cost-effective solutions for the absolute quantification of replication competent lentivirus (RCL) and replication competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies. 


Replication competent viruses (RCVs) can infect cells and replicate to produce additional virions. RCVs can be generated through recombination events between the transfer plasmid and either the production plasmids or the packaging cell line's genome. Fundamental to the safety of emerging cell and gene therapies, RCV testing of samples must be performed throughout the production process. 

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Bio-Rad’s Vericheck ddPCR kits for detection of RCL and RCAAV provide a validated solution for highly specific and highly sensitive detection and quantification of viral replication genes, potentially indicating an RCV. The tests are designed for Bio-Rad's QX Droplet Digital PCR (ddPCR) platforms, with a simple workflow including automated data analysis and flexible sample throughput. Compared to traditional cell culture–based methods for RCV testing, the kits significantly reduce cost and turnaround time, achieving results in as little as 8 hours. 


“As the number of cell and gene therapies entering the market increases, we see a growing emphasis on the need for products to ensure safety and efficacy across production processes. We believe that Droplet Digital PCR solutions can help address this unmet need,” said Carolyn Reifsnyder, Senior Director of Marketing at Bio-Rad. “The introduction of Bio-Rad’s newest Vericheck ddPCR kits for RCL and RCAAV to our growing portfolio reflects our ongoing commitment to providing innovative QC tools to support advances in the cell and gene therapy space.”